About Covista 100 49 mg + 51 mg Tablet
Covista 100 is a tablet containing sacubitril 49 mg and valsartan 51 mg. It is a combination medicine used in heart failure and is taken only under a doctor's supervision.
There are 25 brands of Sacubitril + Valsartan listed in Bangladesh. 8 of them have a lower unit price than Covista 100. The lowest listed price is Arnis 24 mg+26 mg Tablet at ৳ 35.00 per unit.
What is Covista 100 49 mg + 51 mg Tablet?
Covista 100 is a prescription tablet made by Advanced Chemical Industries PLC. It contains two active ingredients: sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin receptor blocker. Together they work to relax blood vessels and reduce strain on the heart. Doctors prescribe it for chronic heart failure with reduced ejection fraction in adults, and for symptomatic heart failure in children aged one year and older. It helps lower the risk of cardiovascular death and hospitalization for heart failure. The dose is decided by the doctor based on the patient's condition and tolerance. Regular monitoring of blood pressure, kidney function, and potassium is needed during treatment.
Uses of Covista 100
Covista 100 is used to treat chronic heart failure with reduced ejection fraction in adults. It helps reduce the risk of cardiovascular death and hospitalization for heart failure. It is also used for symptomatic heart failure with left ventricular systolic dysfunction in children aged one year and older. This medicine is not for treating high blood pressure or any other condition unless prescribed by a doctor. Only a qualified doctor can decide if it is suitable for a particular patient.
How to use Covista 100
Covista 100 is taken by mouth, usually twice a day, with or without food. The doctor decides the exact dose and how long to take it. Swallow the tablet whole with water; do not crush or chew it. Try to take it at the same times each day. If you miss a dose, take it as soon as you remember, but skip it if it is almost time for the next dose. Never take two doses at once. Do not stop or change the dose without talking to your doctor.
Side effects of Covista 100
Common side effects of Covista 100 include angioedema (swelling of the face, lips, tongue, or throat), low blood pressure, reduced kidney function, high potassium levels, cough, and dizziness. Angioedema is serious and needs immediate medical attention. Low blood pressure may cause dizziness or fainting, especially when standing up quickly. Tell your doctor if you notice any side effects or if they bother you. Do not ignore severe symptoms. Your doctor may adjust the dose or recommend tests to monitor your condition.
Safety and precautions
Covista 100 is not safe during pregnancy because it can harm the unborn baby. It is not recommended during breastfeeding. Women who can become pregnant should use effective contraception and tell their doctor if they become pregnant. Do not take this medicine if you have had angioedema related to an ACE inhibitor or ARB, or if you have hereditary angioedema. Avoid taking it with ACE inhibitors or aliskiren if you have diabetes. Before starting, tell your doctor about any kidney or liver problems, low blood pressure, or high potassium. Your doctor will check your kidney function and potassium levels regularly.
Frequently asked questions
What does the generic name Sacubitril + Valsartan mean?
Sacubitril and valsartan are the two active ingredients in Covista 100. Sacubitril belongs to a class called neprilysin inhibitors, and valsartan is an angiotensin receptor blocker. Together they help manage heart failure by relaxing blood vessels and reducing the workload on the heart.
What is Covista 100 used for and what kind of medicine is it?
Covista 100 is a prescription tablet used to treat chronic heart failure with reduced ejection fraction in adults and symptomatic heart failure in children aged one year and older. It is a combination of a neprilysin inhibitor and an angiotensin receptor blocker. It helps reduce the risk of cardiovascular death and hospitalization for heart failure.
Is Covista 100 safe in pregnancy or breastfeeding?
No, Covista 100 is not safe during pregnancy as it can harm the unborn baby. It is also not recommended while breastfeeding. If you are pregnant, planning to become pregnant, or breastfeeding, talk to your doctor about safer alternatives. Use effective contraception during treatment.
What should I tell my doctor before taking Covista 100?
Tell your doctor if you have kidney or liver problems, low blood pressure, high potassium levels, or a history of angioedema. Also mention all other medicines you take, especially ACE inhibitors, ARBs, potassium-sparing diuretics, NSAIDs, or lithium. Your doctor will decide if Covista 100 is suitable for you.
- Strength
- 49 mg + 51 mg
Price in Bangladesh
৳ 76.44 ৳ 78 2% off unit price
Price updated: 16 Nov 2026
Indications
This is indicated:
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
... Read more
This is indicated:
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
- This is usually administered in conjunction with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB.
Pharmacology
This tablet contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. This tablet inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT1 ) receptor via valsartan. The cardiovascular and renal effects of this tablet in heart failure patients are attributed to the increased levels of peptides that are degraded by neprilysin, such as natriuretic peptides, by LBQ657, and the simultaneous inhibition of the effects of angiotensin II by valsartan. Valsartan inhibits the effects of angiotensin II by selectively blocking the AT1 receptor, and also inhibits angiotensin II-dependent aldosterone release.
Dosage & Administration
Adult Heart Failure: The recommended starting dose is 49/51 mg orally twice daily. Double the dose after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.
Reduce the starting dose to 24/26 mg twice daily for:
- Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.
- Patients with severe renal impairment.
- Patients with moderate hepatic impairment.
Pediatric Heart Failure: Refer to Table 1 for the recommended dose for pediatric patients aged one year and older. Take the recommended dose orally twice daily. Adjust pediatric patient doses every 2 weeks, as tolerated by the patient.
Recommended Dose Titration-Pediatric Patients Less than 40 kg:
- Starting: 1.6 mg/kg
- Second: 2.3 mg/kg
- Final: 3.1 mg/kg
Pediatric Patients At least 40 kg, less than 50 kg:
- Starting: 24/26 mg
- Second: 49/51 mg
- Final: 49/51 mg
Pediatric Patients At least 50 kg:
- Starting: 49/51 mg
- Second: 72/78 mg
- Final: 97/103 mg
Interaction
Dual Blockade of the Renin-Angiotensin-Aldosterone System: Should not be used with an ACEi, aliskiren in patients with diabetes, and use with an ARB should be avoided.
Potassium-sparing Diuretics: Serum potassium level may be increased.
NSAIDs: Risk of renal impairment may be increased.
Lithium: Increased risk of lithium toxicity.
Contraindications
This combination is contraindicated:
- In patients with hypersensitivity to any component
- In patients with a history of angioedema related to previous ACE inhibitor or ARB therapy
- With concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor
- With concomitant use of aliskiren in patients with diabetes
Side Effects
The most common side effects are Angioedema, Hypotension, Impaired Renal Function, Hyperkalemia, Cough, Dizziness.
Pregnancy & Lactation
Pediatric Use: Safety and effectiveness have not been established in pediatric patients less than 1 year of age.
Geriatric Use: No relevant pharmacokinetic differences have been observed in elderly (>65 years) or very elderly (>75 years) patients compared to the overall population.
Hepatic Impairment: No dose adjustment is required when administering this tablet to patients with mild hepatic impairment (Child-Pugh A classification). This tablet is not recommended in patients with severe hepatic impairment, as no studies have been conducted in these patients.
Renal Impairment: No dose adjustment is required in patients with mild (eGFR 60 to 90 ml/min/1.73 m2) to moderate (eGFR 30 to 60 ml/min/1.73 m2) renal impairment. The recommended starting dose in patients with severe renal impairment (eGFR <30 ml/min/1.73 m2) is 24/26 mg twice daily.
Precautions & Warnings
This tablet may cause angioedema and must not be used in patients with a known history of angioedema related to previous ACEi or ARB therapy and in patients with hereditary angioedema.
This tablet lowers blood pressure and may cause symptomatic hypotension. Closely monitor serum creatinine, and down-titrate or interrupt this tablet in patients who develop a clinically significant decrease in renal function. In patients with renal artery stenosis, monitor renal function.
Monitor serum potassium periodically and treat appropriately, especially in patients with risk factors for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism, or a high potassium diet. Dosage reduction or interruption of this tablet may be required.
Overdose Effects
Limited data are available with regard to overdosage in human subjects with this tablet. In healthy volunteers, a single dose of this tablet 583 mg sacubitril/617 mg valsartan, and multiple doses of 437 mg sacubitril/463 mg valsartan (14 days) have been studied and were well tolerated. Hypotension is the most likely result of overdosage due to the blood-pressure-lowering effects of this tablet. Symptomatic treatment should be provided. This tablet is unlikely to be removed by hemodialysis because of high protein binding.
Storage Conditions
Keep in a dry place and store below 30°C. Protect from moisture and keep out of the reach of children.
Alternative brands of Sacubitril + Valsartan
Other brands with the same generic name, cheapest first.
See all 25 brands
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.